Medication info
Croujez 10mg (Rosuvastatin Calcium)

Croujez 10mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
DaeWon Pharmaceutical Co., Ltd.
Appearance
Pink, round film-coated tablets
Packaging
For domestic use: 28 tablets (14 tablets/PTP x 2), for export: 28 tablets (14 tablets/PTP x 2)
Approval status
Active

MFDS item code 201000981 · Notified 2010.01.28 · Insurance code 671804830

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased up to a maximum of 20 mg daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.
Child dose
Pediatric patients with heterozygous familial hypercholesterolemia (aged 10 to 17 years): The usual dosage range is 5 mg to 20 mg once daily. Maximum daily dose: 20 mg. Safety and efficacy have not been established in children younger than 10 years.

Ingredients

Manufacturer
DaeWon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is primarily used for various types of lipid disorders associated with hypercholesterolemia. It serves as an adjunct therapy for patients with primary hypercholesterolemia and mixed hyperlipidemia who find it difficult to control their condition through diet and exercise. Additionally, it is effective as a dietary adjunct for special lipid disorders such as homozygous familial hypercholesterolemia or dysbetalipoproteinemia. This medication lowers total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis, and is also used for pediatric patients aged 10 to 17 with heterozygous familial hypercholesterolemia. Furthermore, it helps reduce the risk of stroke, myocardial infarction, and arterial revascularization in men over 50 and women over 60 who have cardiovascular disease risk factors. Thus, this medication is effectively used for various types of dyslipidemia and the reduction of cardiovascular disease risk.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased up to a maximum of 20 mg daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.

Child dose

Pediatric patients with heterozygous familial hypercholesterolemia (aged 10 to 17 years): The usual dosage range is 5 mg to 20 mg once daily. Maximum daily dose: 20 mg. Safety and efficacy have not been established in children younger than 10 years.

Precautions

This drug should not be used in patients with certain allergic reactions. It should not be administered to patients with active liver disease or severe liver function impairment. Patients with muscle-related disorders or muscle damage should not take this medication. It should be avoided in cases where it is taken with cyclosporine due to potential risks. This drug should not be used in patients with significantly impaired kidney function. Women who are pregnant or breastfeeding should not use this medication, and women of childbearing age should only use it when they are highly unlikely to become pregnant. Patients at high risk for muscle damage should particularly avoid high doses, and caution should be exercised in patients with risk factors such as kidney impairment, hypothyroidism, or family history. This medication contains lactose, so it is not suitable for patients with genetic issues such as lactose intolerance. Regular liver function tests and muscle-related tests should be performed during treatment, and if muscle pain or weakness occurs, medical attention should be sought immediately. If symptoms of myalgia or myopathy are severe, discontinue use and consult a physician. This medication may interact with some drugs, so it is essential to inform healthcare providers if other medications are being taken. Particular caution is necessary when used in combination with fibrate-class drugs due to increased risk of muscle damage. This medication may cause rare side effects such as interstitial lung disease or severe skin reactions, so contact healthcare personnel immediately if symptoms such as dyspnea, rash, or fever occur. Pregnant women should not take this medication, and women planning pregnancy should use appropriate contraception. In case of overdose, there is no specific antidote, and treatment should be symptom-based while monitoring liver function and muscle enzyme levels. Dizziness may occur when driving or operating machinery, so caution is advised. This medication may show higher systemic concentrations in Asians, so dose adjustments may be necessary. Blood sugar levels may rise during treatment, so patients at risk for diabetes should manage blood sugar levels thoroughly.

Side effects

Angioedema, hypersensitivity reaction, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms (DRESS), drug-induced licheniform eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, ALT elevation, chest pain, muscle cramps, gout, erectile dysfunction, AST elevation, fatigue, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, fainting, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in an airtight container to avoid exposure to air or moisture, and it is best to keep it at room temperature between 1 to 30 degrees Celsius. Doing this will help maintain the drug's effectiveness and ensure safe use.

Appearance and packaging

Appearance

Pink, round film-coated tablets

Package unit

For domestic use: 28 tablets (14 tablets/PTP x 2), for export: 28 tablets (14 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.